Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia |
Koh, Kyung-Nam
(Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
Park, Mee-Rim (Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) Kim, Bo-Eun (Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) Im, Ho-Joon (Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) Park, Chan-Jeoung (Division of Pediatric Hematology/Oncology, Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) Jang, Seong-Soo (Division of Pediatric Hematology/Oncology, Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) Chi, Hyun-Sook (Division of Pediatric Hematology/Oncology, Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) Seo, Jong-Jin (Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) |
1 | Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139-52. DOI ScienceOn |
2 | Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-43. DOI ScienceOn |
3 | Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008;111:5477-85. DOI ScienceOn |
4 | Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-6. |
5 | Ito S, Ishida Y, Murai K, Kuriya S. Flow cytometric analysis of aberrant antigen expression of blasts using CD45 blast gating for minimal residual disease in acute leukemia and high-risk myelodysplastic syndrome. Leuk Res 2001;25:205-11. DOI ScienceOn |
6 | Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 2009;46:100-6. DOI ScienceOn |
7 | Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000;14:783-5. DOI ScienceOn |
8 | Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 2005;90:382-90. |
9 | Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood lymphoblastic leukemia. Blood 2002;100:52-8. DOI ScienceOn |
10 | Babusikova O, Zeleznikova T, Kirschnerova G, Kankuri E. Hematogones in acute leukemia during and after therapy. Leuk Lymphoma 2008;49:1935-44. DOI ScienceOn |
11 | Park CJ, Kim MC, Moon AR, Seo EJ, Chi HS, Seo JJ, et al. Detection of minimal residual disease by IgH gene rearragnement-PCR in childhood acute lymphoblastic leukemia. Korean J Clin Pathol 1999;19:163-71. |
12 | Stow P, Key L, Cjen X, Pan Q, Neale GA, Coustan-Smith E, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115:4657-63. DOI ScienceOn |
13 | Cui L, Li Z, Wu M, Li W, Gao C, Deng G. Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia. Leuk Res 2010;34:1314-9. DOI ScienceOn |
14 | Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol 2009;146:292-9. DOI ScienceOn |
15 | van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-8. DOI ScienceOn |
16 | Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001;2:409-17. DOI ScienceOn |
17 | Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121:823-38. DOI ScienceOn |
18 | Scrideli CA, de Paula Queiroz R, Bernardes JE, Defavery R, Valera ET, Tone LG. Use of simplified strategies to evaluate early treatment response in childhood acute lymphoblastic leukemia. Leuk Res 2006;30:1049-52. DOI ScienceOn |
19 | Coustan-Smith E, Ribeiro RC, Stow P, Zhou Y, Pui CH, Rivera GK, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006;108:97-102. DOI ScienceOn |
20 | Scrideli CA, Assumpcao JG, Ganazza MA, Araujo M, Toledo SR, Lee ML, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009;94:781-9. DOI ScienceOn |
21 | McKenna RW, Asplund SL, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry. Leuk Lymphoma 2004;45:277-85. DOI ScienceOn |
22 | Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009;27:5168-74. DOI ScienceOn |
23 | Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-- Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591-8. DOI ScienceOn |
24 | Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206-14. DOI ScienceOn |
25 | Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia 2010;24:285-97. DOI ScienceOn |